NASDAQ:PHAT Investor Notice: Investigation over Possible Wrongdoing at Phathom Pharmaceuticals, Inc.
An investigation on behalf of investors in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) shares over potential wrongdoing at Phathom Pharmaceuticals, Inc. was announced.
San Diego, CA -- (SBWire) -- 09/28/2022 --An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Phathom Pharmaceuticals, Inc.
Investors who purchased shares of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Phathom Pharmaceuticals, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.
Florham Park, NJ based Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. On August 2, 2022, before market hours, Phathom Pharmaceuticals, Inc. issued a press release entitled "Phathom Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Updates" which announced that "we detected trace levels of a nitrosamine in vonoprazan drug product in our post-approval testing as we prepared for commercial launch." Further, the press release announced that "[t]he Company is working with the FDA and plans to obtain approval of and implement an additional test method, specification, including a proposed acceptable intake limit, and additional controls to address this impurity prior to releasing our first vonoprazan-based products to the market." Finally, Phathom Pharmaceuticals, Inc. announced that "[t]hese additional activities will result in a delay of the planned VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK product launches."
Those who purchased shares of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
About The Shareholders Foundation
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
Media Relations Contact
Shareholders Foundation, Inc.
View this press release online at: http://rwire.com/1364230